olivLaw · European equity research
RTW Biotech Opportunities Ltd RTW.L
United Kingdom · London Stock Exchange · Vertical: Listed companies from United Kingdom
RTW Biotech Opportunities Ltd is a London-listed investment fund that identifies transformative life sciences assets, from public companies to early-stage private ventures built from inception. Its 2025 performance was marked by a biotech sector recovery, with NAV per share growing by over 35 percent and the discount to net asset value narrowing, which could support investor interest if the trend holds.
At the close of 05 Nov 2026, RTW Biotech Opportunities Ltd (RTW.L) stock was 2.38 USD (−0.42% on the day), with beta 0.49, 52-week range 1.79–2.61 USD.
Data as of · AI analysis dated · Source: ESEF annual reports and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 53.3
- neutral
- Bollinger (20, 2)
- 2.18 – 2.46
- in the upper half of the band · %B 0.70 · band width 12.0%
- SMA 50 / 200
- 2.36 / 2.25
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 0.01 / 0.00
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | EURO STOXX 50 | vs EURO STOXX 50 | Vertical median | |
|---|---|---|---|---|
| 1 month | +2.1% | −0.6% | +2.8 pp | — |
| 3 months | −4.4% | −4.2% | −0.2 pp | — |
| 6 months | +9.2% | +4.3% | +4.8 pp | — |
| Year to date | +10.2% | +7.5% | +2.7 pp | — |
| 1 year | +31.5% | +9.9% | +21.6 pp | +6.7% |
| 3 years | +115.4% | +49.8% | +65.5 pp | +24.8% |
| 5 years | +26.3% | +42.8% | −16.6 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
EPS unavailable in the issuer's structured filings (e.g. a partnership reports per unit, not per share).
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | unavailable | unavailable | unavailable |
| Revenue YoY | unavailable | unavailable | unavailable |
| Net income | 83.2 m | 34.2 m | 245.2 m |
| Net income YoY | unavailable | −58.9% | +617.4% |
| Diluted EPS | unavailable | unavailable | unavailable |
| Diluted EPS YoY | unavailable | unavailable | unavailable |
| net % | unavailable | unavailable | unavailable |
| Free cash flow | unavailable | unavailable | unavailable |
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 6.0 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- unavailable USD
- Total assets
- 1.1 bn USD
- Debt / equity
- unavailable
- Current ratio
- unavailable
- ROE
- unavailable
- ROA
- 26.8%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Income statement · USD
Balance sheet · USD
Cash flow · USD
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 0 of at least 6
- score weight coverage: 0.0% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: unavailable
Key indicators
Coverage and freshness
Score by group
0% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · input data missing
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 0 of at least 6; score weight coverage: 0.0% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | unavailable | unavailable | — |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | unavailable | unavailable | — |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partialunavailable · 0/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partialunavailable · 0/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
RTW BIOTECH OPPORTUNITIES LTD (RTW.L). Latest full fiscal year: 2025; data up to 2025-12-31.
Financial indicators are unavailable.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 0 of at least 6; score weight coverage: 0.0% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
What contradicts it
No signal among the computed factors. That is not an absence of risk: factors without data were not assessed, and business risks (margins, inventory, demand) are in the source-based analysis.
Not assessed (insufficient data or a ratio without meaning): ROIC, Net margin, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, Current ratio, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Listed companies from United Kingdom · same country · compared with 40 companies
Multiples and returns vs the median
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| BATS.LBritish American Tobacco P.L.C. | 104.3 bn | 13.5 | 16.5% | 30.3% | −1.0% | +7% / +88% |
| ABF.LAssociated British Foods PLC | 14.7 bn | 14.3 | 9.2% | 5.3% | −3.1% | −5% / −15% |
| 0EV1.LCarnival PLC | 5.5 bn | 4.1 | 46.7% | 13.4% | +6.4% | unavailable / unavailable |
| BAB.LBabcock International Group PLC | 5.1 bn | 24.7 | 34.7% | 4.1% | +7.2% | −10% / +158% |
| AUTO.LAutotrader Group PLC | 4.8 bn | 16.4 | 60.2% | 47.1% | +3.9% | −13% / −23% |
| BBY.LBalfour Beatty PLC | 4.2 bn | 16.3 | 23.2% | 2.8% | +15.2% | +20% / +160% |
| ABDN.LAberdeen Group PLC | 4.1 bn | 10.8 | 8.0% | 28.9% | −2.1% | +11% / +41% |
| BKG.LThe Berkeley Group Holdings PLC | 3.6 bn | 11.3 | 8.8% | 13.4% | −4.2% | −0% / −22% |
| BME.LB&M European Value Retail PLC | 2.9 bn | 17.4 | 21.2% | 2.8% | +3.7% | +68% / −51% |
| AJB.LAj Bell PLC | 2.4 bn | 22.8 | 49.9% | 33.1% | +18.0% | +8% / +128% |
| ASHM.LAshmore Group PLC | 1.4 bn | 13.9 | 13.1% | 71.6% | −0.1% | +28% / +18% |
| BCG.LBaltic Classifieds Group PLC | 1.2 bn | 23.2 | 15.8% | 57.6% | +6.9% | −99% / −99% |
| APN.LApplied Nutrition PLC | 763.6 m | 36.2 | 41.2% | 19.7% | +24.2% | +71% / unavailable |
| BAG.LA.G. Barr P.L.C. | 671.9 m | 14.4 | 14.4% | 10.8% | +4.0% | −7% / +26% |
| ASC.LAsos PLC | 494.5 m | — | -81.3% | -12.0% | −14.7% | +71% / +8% |
| ALFA.LAlfa Financial Software Holdings PLC | 486.8 m | 16.3 | 61.5% | 23.8% | +15.3% | −28% / +10% |
| AML.LAston Martin Lagonda Global Holdings PLC | 344.3 m | — | -93.4% | -39.2% | −20.6% | −45% / −85% |
| APTD.LAptitude Software Group PLC | 111.3 m | 28.5 | 7.2% | 6.2% | −7.3% | −30% / −23% |
| BMS.LBraemar PLC | 78.3 m | 39.2 | 2.7% | 1.7% | −4.4% | +13% / −11% |
| AMGO.LAmigo Holdings PLC | 9.9 m | — | — | — | −81.9% | +325% / +844% |
| ASBE.LAssociated British Engineering PLC | 605.3 k | — | -19.1% | — | unavailable | unavailable / unavailable |
| AMIF.LAmicorp Fs (uk) PLC | 221.6 k | 0.1 | 27.5% | 9.1% | +8.1% | unavailable / unavailable |
| AAF.LAirtel Africa PLC | — | — | 24.1% | 10.6% | +29.5% | −7% / +164% |
| AAL.LAnglo American PLC | — | — | -19.3% | -20.2% | +4.5% | +30% / +76% |
| ACG.LAcg Metals Limited | — | — | -80.3% | -32.0% | +134.8% | +60% / +63% |
1- and 3-year price returns: for RTW.L from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
RTW Biotech Opportunities Ltd is a London-listed investment fund that identifies transformative life sciences assets, from public companies to early-stage private ventures built from inception. Its 2025 performance was marked by a biotech sector recovery, with NAV per share growing by over 35 percent and the discount to net asset value narrowing, which could support investor interest if the trend holds.
SWOT
Strengths
- Deep scientific expertise and the manager's network allow early identification of high-potential assets. A portfolio spread across public, private and royalty holdings offers flexibility.
- The fund delivered a NAV return above most sector references in 2025, and its ability to finance companies from inception is a distinctive advantage.
- Inclusion in FTSE indices raised the company's visibility and share liquidity, which can support its shareholder base.
Weaknesses
- The private component declined in 2025, showing that valuations can take time to reflect real company progress.
- Concentration in a few large holdings, such as PTC Therapeutics, exposes the fund to company-specific risks.
- The company pays no dividend, so shareholder returns depend mainly on growth in net asset value and narrowing of the discount.
Opportunities
- Mergers and acquisitions in pharmaceuticals could create new liquidity events for the portfolio.
- If the discount to net asset value keeps narrowing, the shares could better reflect the portfolio's value.
- Buyback programmes and reinvestment of royalty cash flows could support growth in value per share.
Threats
- Tariffs, drug pricing policies and FDA oversight could affect the valuations of companies in the portfolio.
- Clinical setbacks or development problems at portfolio companies can quickly reduce the value of positions.
- A still-limited IPO market could delay the realisation of value from private investments.
Risks
- Concentration in a few positionshigh
A significant share of NAV is concentrated in a small number of companies, and negative events at those companies could materially affect fund results.
- Private valuation riskmedium
Valuations of private investments are estimates that can be revised, and negative adjustments may occur before value is realised.
- Regulatory riskmedium
Changes in drug pricing policies or FDA approvals could influence the valuations of companies in the portfolio.
- Discount to net asset value riskmedium
Shares may continue to trade at a discount to net asset value, and a wider discount could reduce shareholder returns.
- Liquidity risklow
Exits from private investments depend on capital markets and transactions, which could be delayed if conditions deteriorate.
Investment thesis
What would need to be true (bull case)
- If the biotech sector recovery consolidates, the value of both public and private holdings could keep rising, and the discount could narrow further.
- Takeovers in pharmaceuticals could produce further profitable exits from the fund's positions, supporting growth in net asset value.
- The royalty component could offer steadier income and help cushion the volatility of biotech shares.
What would break the thesis
- If tariffs or drug pricing pressure intensify, valuations of portfolio companies could fall.
- A weak IPO market could delay the realisation of value from private investments and keep valuations below expectations.
- Concentration in a few large positions could amplify losses if one of those companies suffers clinical failure.
What to watch
- Development of the discount to net asset value and the share price2026
- Annual General Meeting and portfolio updates11 June 2026
- Progress of mergers and acquisitions involving portfolio companies2026
- Results of private investments and any valuation adjustmentsNext annual report
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
The Group operates as a life sciences investment fund managed by RTW Investments, LP, building its portfolio through active and passive investments in biopharmaceutical and medical technology companies worldwide. Its strategy pairs deep scientific research with a long investment horizon and the capacity to form new companies from early stages. Shares have been listed on the London Stock Exchange since October 2019.
At 31 December 2025, net asset value attributable to ordinary shareholders stood at US$800.9 million 1, with roughly 71 percent of NAV in public positions, 24 percent in private positions and about 2.3 percent in royalties. The fund intends to invest around 80 percent of gross assets in biopharmaceuticals and 20 percent in medical technology, with allocations that can be rebalanced as opportunities arise.
Beyond equity investments, the group holds royalty positions through the 4010 Royalty Fund, managed by the same investment manager, which adds more stable income and a return profile less correlated with biotech share volatility. In 2025 the company also continued a share buyback programme, one of the tools it uses to address the discount to net asset value.
Segments
Public portfolio
Public positions make up most of the fund and drove the largest share of gains in 2025. The biggest holdings, such as PTC Therapeutics at about 11.6 percent of NAV at year-end 1, benefited from regulatory and commercial progress at the companies involved.
Private portfolio
Private investments target early and mid-stage companies, including de novo ventures formed by the manager. This component declined in 2025 amid valuation adjustments, but the fund considers that value could be realised over the longer term through liquidity events.
Royalties
Royalties, representing about 2.3 percent of NAV at year-end 2025 1, added roughly 0.9 percentage points to NAV through the 4010 Royalty Fund. They relate to approved products such as Lumryz and Jelmyto and provide a more predictable income component.
Market context
The biotech sector ended a multi-year stretch of underperformance against the S&P 500 in 2025, which the company describes as the close of a four-year bear market. Mergers and acquisitions accelerated, and the fund's returns were compared with indices such as the Russell 2000 Biotech and the Nasdaq Biotech, which returned 44.6 percent and 33.4 percent respectively 1.
The initial public offering market remained limited, and the manager views the sector's recovery as still at an early stage. Tariffs, drug pricing and FDA oversight remain the main risk areas, although structural factors such as more disciplined capital allocation and strategic transactions could support longer-term values.
Trends
- Mergers and acquisitionstailwind
Takeover activity increased in 2025, generating gains for the fund through exits from positions. If large pharmaceutical companies continue to seek pipeline replenishment, this could support the realisation of value from the portfolio.
- Narrow IPO marketheadwind
Initial public offerings remained scarce, limiting listing-based liquidity options. The fund stressed the importance of alternative routes to realisation, but this constraint could slow exits from private investments.
- Regulatory and pricing pressuremixed
Tariffs, drug pricing policies and FDA oversight contributed to volatility in 2025. Their impact depends on future decisions, and the effect on valuations could be significant.
- Biotech recoverytailwind
The company believes structural factors, such as capital discipline and a clearer path from innovation to revenue, can support sector growth. If this recovery consolidates, it could influence both portfolio valuations and the share discount.
Competitive position
The fund competes with other specialist biotech and healthcare investors, both listed funds and private venture investors. Its differentiation comes from combining public and private investments with the capacity to build new companies, alongside its royalty activity.
Comparison with indices and sector vehicles such as the AIC Biotechnology and Healthcare Sector suggests the fund's 2025 performance was above the sector average but below some US references. This indicates that relative returns depend on market context and company selection.
- US-focused biotech investment funds
Investment funds targeting biotech and pharmaceutical companies in US markets, with selection strategies comparable to the fund's.
- Russell 2000 Biotech index
Reference index used by the company which returned more than the fund in 2025, reflecting a smaller-cap segment of the market.
- Nasdaq Biotech index
Benchmark for biotech companies listed on Nasdaq, used to compare the performance of the public portfolio.
- Healthcare venture capital funds
Private investors funding early-stage companies, competing with the fund for access to promising projects.
News & filings
In the press
No news in our archive over the last 180 days.
Annual reports (ESEF)
- Annual report 202529 Apr 2026
- Annual report 202423 Apr 2025
Sources
- [1] Annual report, fiscal year ended 2025-12-31 (ESEF) · SEC / RTW Biotech Opportunities Ltd · 31 Dec 2025
Figures computed by olivLaw from ESEF annual reports and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.